SCHEMBL4419734

SCHEMBL4419734

CN(CP(=O)(ON)Oc1ccc([N+](=O)[O-])cc1)S(=O)(=O)c1cccs1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
HPGD P15428 2/20 0.42
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
MAPT P10636 3/20 0.40
TDP1 Q9NUW8 1/20 0.40
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
BCHE P06276 1/20 0.39
ACHE P22303 1/20 0.39
CYP3A4 P08684 3/20 0.38
MAPK1 P28482 2/20 0.38
HSD17B10 Q99714 2/20 0.38
LMNA P02545 1/20 0.38
TP53 P04637 1/20 0.38
THRB P10828 1/20 0.38
CES2 O00748 1/20 0.38
CES1 P23141 1/20 0.38
TSHR P16473 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL4419736 0.84 CA1 (0.44) ALDH1A1SMN1; SMN2HPGDMEN1KMT2A
SCHEMBL4421229 0.82 MAPT (0.40) ALDH1A1SMN1; SMN2MEN1KMT2AMAPT
SCHEMBL4430978 0.74 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2HPGDMEN1KMT2A
SCHEMBL4421232 0.71 CA2 (0.36) ALDH1A1SMN1; SMN2HPGDMEN1KMT2A
SCHEMBL6383366 0.71 MEN1 (0.38) ALDH1A1SMN1; SMN2MEN1KMT2AMAPT
SCHEMBL3222070 0.70 CA1 (0.47) ALDH1A1MEN1KMT2AMAPTTDP1
SCHEMBL7127961 0.69 SMN1; SMN2 (0.59) ALDH1A1SMN1; SMN2HPGDMEN1KMT2A
SCHEMBL4431396 0.69 CA1 (0.46) ALDH1A1MEN1KMT2AMAPTTDP1
SCHEMBL4430060 0.68 NR3C1 (0.39) ALDH1A1SMN1; SMN2MEN1KMT2AMAPT
SCHEMBL4431537 0.68 PLAU (0.40) ALDH1A1SMN1; SMN2MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514556-B2 Inhibitors of β-lactamase METHYLGENE INC. (CA) 2009-04-07 US disclosed
US-20070293675-A1 Novel Inhibitors Of Beta-Lactamase METHYLGENE, INC. (CA) 2007-12-20 US disclosed
US-7259172-B2 phenyl or thien-2-yl substituted amide methyl phosphonate or phosphonyl halide derivatives; do not require a beta -lactam pharmacophore; bactericides; antibiotic resistance METHYLGENE INC. (CA) 2007-08-21 US disclosed
US-20060105999-A1 Novel inhibitors of beta-lactamase METHYLGENE, INC. (CA) 2006-05-18 US disclosed
US-7030103-B2 Sulfonamidomethyl phosphonate inhibitors of β-lactamase METHYLGENE, INC. (CA) 2006-04-18 US disclosed
EP-1194436-B1 SULFONAMIDOMETHYL PHOSPHONATE INHIBITORS OF BETA-LACTAMASE METHYLGENE INC (CA) 2005-11-30 EP disclosed
US-6921756-B2 Inhibitors of β-lactamase METHYLGENE, INC. (CA) 2005-07-26 US disclosed
US-6884791-B2 Inhibitors of β-lactamase METHYLGENE, INC. (CA) 2005-04-26 US disclosed
US-20050043276-A1 Novel inhibitors of beta-lactamase METHYLGENE, INC. (CA) 2005-02-24 US disclosed
WO-2004048393-A2 NOVEL INHIBITORS OF β-LACTAMASE METHYLGENE, INC. (CA) 2004-06-10 WO disclosed
US-20040082546-A1 Novel Inhibitors of beta-lactamase METHYLGENE, INC. 2004-04-29 US disclosed
US-20040059115-A1 Novel sulfonamidomethyl phosphonate inhibitors of beta-lactamase 92229129 QUEBEC INC. (CA) 2004-03-25 US disclosed
US-20040029836-A1 Novel inhibitors of beta-lactamase 92229129 QUEBEC INC. (CA) 2004-02-12 US disclosed
US-6472406-B1 Sulfonamidomethyl phosphonate inhibitors of beta-lactamase METHYLGENE, INC. (CA) 2002-10-29 US disclosed
EP-1194436-A1 SULFONAMIDOMETHYL PHOSPHONATE INHIBITORS OF BETA-LACTAMASE Methylgene, Inc. (CA) 2002-04-10 EP disclosed
WO-2001002411-A1 SULFONAMIDOMETHYL PHOSPHONATE INHIBITORS OF β-LACTAMASE METHYLGENE INC. (CA) 2001-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043276-A1 Novel inhibitors of beta-lactamase MGAM, LSS, CYP51A1 ALDH1A1 1276/4885SMN1; SMN2 4705/4885HPGD 259/4885
US-20040029836-A1 Novel inhibitors of beta-lactamase LSS, MGAM, COASY ALDH1A1 1038/4885SMN1; SMN2 4722/4885HPGD 307/4885
US-20060105999-A1 Novel inhibitors of beta-lactamase LSS, MGAM, LCT ALDH1A1 1276/4885SMN1; SMN2 4759/4885HPGD 328/4885
US-20040059115-A1 Novel sulfonamidomethyl phosphonate inhibitors of beta-lactamase PGLS, MGAM, STS ALDH1A1 2218/4885SMN1; SMN2 4202/4885HPGD 1380/4885
US-20070293675-A1 Novel Inhibitors Of Beta-Lactamase MGAM, LSS, CYP51A1 ALDH1A1 1276/4885SMN1; SMN2 4705/4885HPGD 259/4885
US-20040082546-A1 Novel Inhibitors of beta-lactamase LSS, MGAM, COASY ALDH1A1 1007/4885SMN1; SMN2 4721/4885HPGD 346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.